부산대학교 도서관

Esophageal carcinomas frequently metastasize to the liver. Current systemic therapies have response rates of 30%, with a median survival of 6 to 10 months and a 1-year survival of 30 to 40%. We evaluated response and survival following chemoembolization among eight patients with liver-dominant metastatic esophageal cancer. Imaging, clinical, and laboratory evaluations were performed prior to treatment, 1 month after, and every 3 months thereafter. Kaplan-Meier analyses were performed to estimate the time to progression and survival. One-year survival from the diagnosis of esophageal cancer was 88% (median 20 months), from the diagnosis of liver metastases was 75% (median 16 month), and from the initial chemoembolization was 42% (median 12 months). The 30-day mortality was 0%. Our limited experience suggests that disease stabilization may be achieved following chemoembolization of hepatic metastases from esophageal carcinoma, with survival exceeding previous reports for systemic therapy alone. To our knowledge, there are no other reports of liver-directed therapy for this disease. [ABSTRACT FROM AUTHOR]